NanoViricides, Inc. (NYSE American: NNVC) has announced that its broad-spectrum antiviral candidate, NV-387, merits evaluation as a potential treatment for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company noted the absence of approved vaccines or therapies specifically targeting this virus strain, highlighting the urgent need for effective interventions.
NV-387's host-targeted antiviral mechanism and oral formulation could offer significant advantages in outbreak settings where treatment delivery and healthcare worker safety are critical. The drug is already being prepared for a Phase II clinical trial in the Democratic Republic of Congo for mpox, which could support near-term regional availability if found effective against Ebola. The company's press release can be found at https://ibn.fm/aSF5Z.
NanoViricides is a clinical-stage company specializing in nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates and technology are based on intellectual property from TheraCour Pharma, Inc. The company holds a broad, exclusive, sub-licensable license to drugs developed in several fields from TheraCour. Its lead candidate, NV-387, is being developed to treat RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as mpox/smallpox and measles. Another advanced candidate is NV-HHV-1 for shingles.
The company's NV-CoV-2 (API NV-387) is a nanoviricide drug candidate for COVID-19, while NV-CoV-2-R encapsulates remdesivir. NanoViricides is also developing drugs against herpes, viral eye diseases, influenza, HIV, Hepatitis C, rabies, dengue, and Ebola. Its platform technology is based on the TheraCour nanomedicine technology, for which NanoViricides holds a worldwide exclusive perpetual license for several human viral diseases, including HIV/AIDS, Hepatitis B and C, rabies, herpes simplex and varicella-zoster, influenza, dengue, Japanese encephalitis, West Nile, Ebola/Marburg, and certain coronaviruses. The company intends to obtain licenses for RSV, poxviruses, and enteroviruses if initial research is successful.
As with any drug development, there is no assurance that NV-387 or any other candidate will demonstrate sufficient effectiveness and safety for human clinical development. The company's path to typical drug development is lengthy and requires substantial capital. Investors can find the latest news and updates on NNVC at https://ibn.fm/NNVC.
